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Objective: To determine if simple adherence measures, such as twenty-four hour recall and 
reﬁ  ll history, are accurate for routine use, compared to more time-consuming measures such 
as pill counts.
Design: Randomized, double-blind, placebo-controlled trial.
Setting: Walter Reed Army Medical Center, a tertiary medical center in Washington.
Patients: Men and women >30 years old with known coronary heart disease and taking a 
statin medication.
Intervention: Clinical pharmacists met with patients for adherence assessments.
Main outcome measures: Adherence was measured by pill counts, twenty-four hour recall by 
patient, and reﬁ  ll history per computer record. Temporal changes in these adherence measures 
were assessed using general linear models for repeated measures.
Results: Adherence was consistently greater for the experimental agent than for the statin 
therapy (n = 148). Mean pill count adherence for statin drug was 78.7 ± 25.2% compared to 
93.5 ± 11.6% (P < 0.001) for the study agent. Reﬁ  ll history and twenty-four hour recall inac-
curately measured adherence when compared to pill counts. Adherence, as determined by pill 
count, for both experimental (P = 0.029) and statin therapy (P = 0.015) showed signiﬁ  cant vari-
ability across time in general linear models. Neither reﬁ  ll history nor twenty-four hour recall 
was sensitive to temporal changes.
Conclusions: Twenty-four hour recall and reﬁ  ll history inaccurately measure medication 
adherence for both clinical trial and clinical practice pharmacotherapies. Further, these measures 
are insensitive to changes in adherence. For a single or multiple assessments across time, pill 
count more accurately measures medication adherence. Pill count should be the standard for 
monitoring medication adherence for both clinical trials and clinical practice.
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Introduction
Adherence to prescribed medications, both in research trials and in clinical practice, is 
crucial to the success of the pharmacologic interventions. However, for both settings 
there is no accepted standard method of assessing adherence, both as a cross sectional 
measurement and for measurements across time (Gordis 1984; Mattson et al 1984; 
Norell 1984; Cramer et al 1989; Rudd et al 1989; Avorn et al 1998; Farmer 1999; Liu 
et al 2001; Benner et al 2002; Garber et al 2004). The latter is crucial to understanding 
the success of pharmacy adherence programs. Frequently reported methods of measur-
ing medication adherence include patient self-report, the use of electronic databases for 
prescription claims or reﬁ  ll history, and the use of pill counts. In general, pill counts are 
regarded as being more accurate than self-report or reﬁ  ll history (Inui et al 1981; Stewart 
1987; Botelho et al 1992; Choo et al 1999; Hamilton 2003). However, pill counts are 
tedious and difﬁ  cult to administer, thus an understanding is needed of the quantitative 
disagreement with easier methods such as twenty-four hour recall and reﬁ  ll history.Therapeutics and Clinical Risk Management 2007:3(4) 686
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Objective
We compared pill count, twenty-four hour recall and reﬁ  ll 
history, and their temporal relationships for both an experi-
mental and clinical drug in a prospective, blinded clinical 
trial. Our objective was to determine if simple adherence 
measures, such as twenty-four hour recall and reﬁ  ll history, 
are sufﬁ  ciently accurate for routine use, compared to more 
time-consuming measures such as pill counts.
Methods
ARBITER 2 was a prospective double-blind, randomized 
clinical trial comparing the efficacy of extended-release 
prescription niacin (Niaspan®, Kos Pharmaceuticals Inc., 
Cranbury, NJ) and matching placebo on the rate of atheroscle-
rosis progression. The study was conducted from December 
2001 to May 2004. By study design, all patients had known 
coronary heart disease and were required to already be taking 
a statin medication prior to study entry and continue taking 
the statin medication throughout the duration of the study. The 
trial was conducted at Walter Reed Army Medical Center, a 
tertiary medical center, and the protocol was approved by the 
institution’s Department of Clinical Investigation. All volun-
teers provided written, informed consent.
A dedicated research pharmacy, which manages all 
medications provided for approved protocols, dispensed 
the study medication. Statin therapy was dispensed by the 
main outpatient pharmacy of the facility along with the 
remainder of the participant’s medications. The majority 
(93%) of patients in the study used simvastatin, the primary 
statin provided by the Department of Defense, with the 
remainder prescribed atorvastatin. All participants met with 
one of the six clinical pharmacists, per study protocol, for 
planned adherence assessments of their study drug and statin 
medication. After an initial meeting at 30 days, adherence 
assessments were performed at 90, 180, 270, and 365 days 
for the 148 study patients. Of these, 14 participants (9.5%) 
forgot to bring their statin bottles to their study visit, (but 
did partake in study drug pill counts). These subjects are 
excluded from some analyses where noted. Participants 
were instructed to bring their medication bottles to each 
visit. Pill counts were calculated as the number of pills 
taken (the number of pills dispensed – the number of pills 
counted). The number of pills expected to have been taken 
was calculated by multiplying the daily dose (1/2, 1 or 2 
tablets) by the number of days since the date dispensed. We 
a priori and rigorously deﬁ  ned successful adherence on pill 
counts as 85–100% of the pills taken during each follow-up 
period (Krueger et al 2003). Adherence per drug use by 
twenty-four hour recall was assessed based on the patient’s 
verbal response (from memory or with an aid of a personal 
medication list) of all of the chronic medications taken 
(including the study and statin medications) within 24 hours 
prior to each pharmacy visit. We considered the patients to 
be adherent according to the twenty-four hour recall if they 
were able to report taking all of their chronic medications. 
Adherence per reﬁ  ll history was determined by assessing the 
electronic pharmacy record system (Composite Health Care 
System, CHCS) to quantify the number of pills dispensed 
relative to time. Adherence was noted if all of the patient’s 
chronic medication reﬁ  lls were consistent with the number 
of days dispensed by the pharmacy, always within 90-days. 
All patients received statin and study medications from the 
military health care system.
The 148 study participants were seen and interviewed 
in a Pharmacy Outcomes Clinic at Walter Reed Army 
Medical Center throughout the study duration (up to 1 year). 
Pharmacists working in the clinic received training in each 
of the adherence assessment and documentation. Data were 
collected on a custom data collection form including written 
reminders on adherence assessment methods and adherence 
deﬁ  nitions. A data dictionary was collectively reviewed and 
discussed among the participating pharmacists in order to 
minimize the potential for inter-rater variability.
At the conclusion of each visit, the remaining study 
medication was taken and returned to the research phar-
macy and a new drug supply was provided. This ensured 
that the exact start and end date of the pill count assessment 
was clearly documented. Participants were responsible for 
reﬁ  lling their statin medication through the main outpatient 
pharmacy on schedule.
Mean pill counts for statin and study drug were computed 
and expressed as the mean ± standard deviation. Means 
were compared using paired t-tests or t-tests for indepen-
dent groups, as appropriate. Temporal changes in pill count 
adherence were assessed using general linear models during a 
monitoring phase of up to 1 year. All analyses were conducted 
using SPSS statistical software (v 13.0; Chicago, IL). A P 
value 0.05 was considered statistically signiﬁ  cant.
Results
A total of 148 subjects participated in pill counts of the 
study medication and assessment provided by the pharmacy 
intervention team. One-hundred thirty four subjects par-
ticipated in pill counts of the statin medication. The mean 
age was 67 ± 10 years, 92% were men. All had a history 
of prior coronary heart disease (by study design) and had Therapeutics and Clinical Risk Management 2007:3(4) 687
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a high prevalence of cardiovascular risk factors including 
hypertension in 74.3% and diabetes mellitus in 27.7%. Most 
subjects, 86.3%, had a complex pharmacy regimen, deﬁ  ned 
as taking greater than 5 daily medications and/or 12 or more 
medication doses per day. 32.9% of the participants were 
taking multiple daily doses, deﬁ  ned as medications taken 3 
or more times per day.
Adherence was consistently greater for the experimental 
agent (n = 148) than for the statin therapy (n = 134). The mean 
pill count for statin drug at 90, 180, 270 and 365 days was 
78.7 ± 25.2% (n = 133; note the difference of 1 patient’s miss-
ing pill count for this measure) compared to 93.5 ± 11.6% 
(n = 148) (P < 0.001) for the study agent. This differential 
was consistently observed across the 12 month observation 
period (Figure 1). Despite this within group stability or 
persistence, there was a substantial degree of intra-subject 
variability in pill counts. Adherence for both experimental 
(P = 0.029) and statin therapy (P = 0.015) showed signiﬁ  cant 
variability across time in general linear models.
Twenty-four hour recall and reﬁ  ll history were insensitive 
to changes in pill counts over time. To assess this, we com-
pared the maximum differential between separate pill counts 
for subjects who either were or were not always adherent by 
recall or reﬁ  ll history as deﬁ  ned under Methods. This analysis 
was limited to subjects in whom at least 3 of the 4 possible pill 
counts were completed (statin, n = 85; study drug, n = 126) 
in order to provide a more stable estimate of pill count differ-
ential. The proportion of subjects who were always adherent 
according to recall and reﬁ  ll history was 58.8% and 60.1%, 
respectively. The maximum differential in pill counts across 
the various time points (eg, 90 days vs. 180 days) in adherent 
subjects was similar to that observed in subjects considered 
nonadherent when categorized either by twenty-four hour 
recall (Figure 2A) or reﬁ  ll history (Figure 2B) [P = NS for all 
comparisons]. Among participants who were always adherent 
by reﬁ  ll history, the maximum differential of pill counts to 
statin agent was 43.6 ± 28.0% vs 36.8 ± 20.4% in those who 
were not always reﬁ  ll adherent (P = NS).
The mean number of pill counts completed per patient 
(maximum of 4 possible pill counts occurring at 90, 180, 270, 
and 365 days) was 3.4 ± 0.9. The relationship for adherence 
assessments using pill counts compared to either twenty-four 
hour recall or reﬁ  ll history were different for study drug and 
statin therapy. Both twenty-four hour recall and reﬁ  ll history 
underestimated adherence for the study drug, and overesti-
mated adherence for statin agent, compared to the pill count 
assessment (Table 1).
Discussion
Understanding adherence to pharmacotherapies is crucial 
in clinical practice and research studies to ensure optimal 
clinical outcomes and valid study results. Research in this 
ﬁ  eld has been limited by the lack of a true gold standard, 
recognizing that each method has strengths and weaknesses 
(Evans et al 1983; Mattson et al 1984; Craig 1985; Wright 
1993; Grymonpre et al 1998; Choo et al 1999; Farmer 1999; 
Schwed et al 1999). Methods used in clinical practice are 
typically simple assessments of medication reﬁ  ll history 
or a patient-recall assessment (Fletcher et al 1979; Stewart 
1987; Christensen et al 1997; Grymonpre et al 1998). These 
methods are easy to perform; however, they are more crude 
and their accuracy is limited. Although some suggest that 
the patient-recall and reﬁ  ll history assessments are accurate 
enough, especially when performed in combination (Mattson 
et al 1984; DiMatteo et al 2002; Farley et al 2003), these 
methods are generally regarded to substantially overesti-
mate medication adherence (Haynes et al 1980; Inui et al 
1981; Stewart 1987; Grymonpre et al 1998; Farmer 1999; 
Shalansky et al 2004). Additionally, the ability of the patient-
recall and reﬁ  ll history to detect changes in adherence is 
unknown. In comparison, pill counts are laborious and rely 
upon the assumption that medications missing from the pill 
Table 1 Mean pill counts vs 24-hour recall and reﬁ  ll history adherence assessments across 12 months
  N*  Study agent  P values  N#  Statin  P values
   Pill count  24-hour     Pill count  24-hour
     recall       recall
Pill count vs 147  93.5  ± 11.6  85.7 ± 20.2  <0.001  134  78.3 ± 25.6  85.8 ± 21.3  0.009
24-hour recall
   Pill count  Reﬁ  ll history     Pill count  Reﬁ  ll history
Pill count vs 148  93.5  ± 11.6  81.9 ± 24.9  <0.001  133  78.7 ± 25.2  82.3 ± 25.2  0.225
Reﬁ  ll history
(Mean ± SD)
*Missing one twenty-four hour recall data.
#Missing one statin pill count data.Therapeutics and Clinical Risk Management 2007:3(4) 688
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bottle were taken (Norell 1984; Rudd et al 1988; Cramer et al 
1989; Farmer 1999). They also rely upon accurate reporting 
dates for starting prescriptions but can be more precise when 
carefully performed as in this study.
This study compared the longitudinal relationships 
among different methods of measuring medication adher-
ence to both a study drug (placebo or extended-release 
prescription niacin) and the “control” clinical medication, 
their statin prescription. Our analysis has shown important 
differences in adherence between study and clinical medica-
tions, differences in the ability of twenty-four hour recall 
and reﬁ  ll history to detect nonadherence, and insensitivity 
of twenty-four hour recall and reﬁ  ll history to detect tem-
poral changes in adherence. Pill count assessment not only 
showed the differences in patient adherence to study agent 
and clinical therapy, but reported the rate of adherence 
(from which we can detect nonadherence) and the changes 
in adherence across time (intra-subject variability). The 
observed differences in study and clinical medications are 
of interest. Although this study cannot provide the cause 
of this observation, it is likely that study participants were 
inﬂ  uenced by the intervention of the clinical pharmacists 
providing their study medication and observing their medi-
cation taking behavior.
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Figure 2 Maximum differential in pill-counts expressed as the greatest difference in pill counts between 90, 180, 270 and 365 day assessments in groups of patients catego-
rized as adherent or nonadherent for 24-hour recall (Panel A) and reﬁ  ll history (Panel B).
A B
Figure 1 Temporal pattern of pill-count adherence across 12 months for both statin (Panel A) and study drug (Panel B).Therapeutics and Clinical Risk Management 2007:3(4) 689
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Strengths of our study, performed within a cardiovascular 
disease population prescribed multiple additional pharma-
cologic agents, include its overall low attrition rate (Taylor 
et al 2004), quantitative data, inclusion of multiple drugs 
and manners of adherence assessments, and its longitudinal 
design. Even though nonadherence has been shown to be 
common in clinical practice, patients in this study were gener-
ally adherent despite complex medical regimens.
Limitations
The generalizability of our ﬁ  ndings is limited by the applica-
tion in a population of patients consenting to a clinical trial, 
who may more closely follow health advice and be interested 
in their health. Because there were six clinical pharmacists 
assessing the medication adherence for this study, there is a 
potential for inter-rater variability even though we instituted a 
standardized training for them. Since the clinical agent, statin, 
was not provided by the research pharmacy, some forgot to 
bring the bottles for pill count, hence the 14 subjects excluded 
from some analysis. Also, the scope of this study was limited 
by our inability to include other types of adherence measures 
such as electronic prescription bottles and drug blood levels 
(direct measures of adherence).
Conclusion
We found that twenty-four hour recall and refill history 
inaccurately assess medication adherence compared to 
pill counts for both clinical trial and clinical practice 
pharmacotherapies. Further, twenty-four hour recall 
and refill history are insensitive to temporal changes 
in adherence when assessed longitudinally. From these 
data, we conclude that pill count is a superior method of 
medication adherence assessment compared to twenty-
four hour recall and refill history in both clinical practice 
and long term medication studies. Pill counts should serve 
as the standard for monitoring patient adherence for both 
experimental and clinical drugs.
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